8 To 10 Amino Acid Residues In Defined Sequence Patents (Class 530/328)
-
Publication number: 20140127139Abstract: The application relates to a compound of general formula (I) below: Signal-Linker-Peptide??(I) and to the uses thereof for medical imaging or diagnosis or the preparation of a composition for diagnosis of an MUC5AC pathological condition.Type: ApplicationFiled: November 30, 2011Publication date: May 8, 2014Applicant: GuerbetInventors: Sébastien Ballet, Walter Gonzalez, Yannick Rossez
-
Patent number: 8716247Abstract: The embodiments include methods of treating conditions requiring removal or destruction of cellular elements, such as benign or malignant tumors in humans, using compounds based on small peptides. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier.Type: GrantFiled: November 28, 2011Date of Patent: May 6, 2014Assignee: Nymox CorporationInventors: Paul Averback, Jack Gemmell
-
Patent number: 8715684Abstract: A novel peptides are complexed with HIV-I envelope protein gp120, and causes the protein to assume a CD4i conformation but without occluding the CD4 binding-site of gp120. This peptide-gp120 complex is immunogenic and, upon immunization of subjects, induces broadly-neutralizing antibodies directed to the CD4 binding site of gp120. The peptide preferably consists of a sequence of 8-20 amino acid residues which comprises (a) a core sequence Arg-Xaa1-Asp-Leu-Pro-Xaa2-Trp-Ala (SEQ ID NO: 1) in which Xaa1 and Xaa2 is any amino acid, or (b) certain substitution variants of SEQ ID NO:1.Type: GrantFiled: August 28, 2008Date of Patent: May 6, 2014Assignee: Ramot at Tel Aviv University Ltd.Inventors: Jonathan M. Gershoni, Gal Dela
-
Publication number: 20140121170Abstract: Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors using the novel peptides.Type: ApplicationFiled: August 30, 2013Publication date: May 1, 2014Inventors: Vincent Craig BOND, Michael POWELL, MingBo HUANG, Syed ALI, Andrea D. RAYMOND, Martin Neville SHELTON, Francois Jean VILLINGER
-
Patent number: 8709998Abstract: The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions.Type: GrantFiled: April 21, 2004Date of Patent: April 29, 2014Assignee: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Yeelena Shen, Jeanne Mary Comstock, Sun H. Kim
-
Patent number: 8710014Abstract: The present invention provides compounds for disrupting the binding of a matrix metalloprotease (MMP) protein to a substrate protein at an interaction site other than the protease catalytic site. In particular the inventive compounds inhibit the MMP's ability to cleave a substrate protein. In some cases the compound may prevent activation of transforming growth factor beta (TGF?). The compounds are preferably polypeptide fragments of the hemopexin-like domain of the MMP, but may be mimetics thereof or peptides or mimetics of the portion of the MMP substrate protein to which the MMP interacts.Type: GrantFiled: October 7, 2011Date of Patent: April 29, 2014Assignee: ProteaPex Therapeutics LLCInventors: Marina D'Angelo, Abdulhafez Selim
-
Patent number: 8710183Abstract: A compound comprising a peptide moiety comprising, consisting essentially of, or consisting of, the peptide sequence of a tyrosine cluster YC of the BY-kinase of a Gram positive or Gram negative bacteria, or a fragment or an analogue thereof, and an adenine peptide analogue PNA(A), whereas the peptide moiety and the PNA are linked together. The compound is useful as an inhibitor of bacterial tyrosine kinase.Type: GrantFiled: May 4, 2009Date of Patent: April 29, 2014Assignee: Centre National de la Recherche Scientifique (C.N.R.S.)Inventors: Christophe Louis Antoine Grangeasse, Sylvie Marianne Nessler, Solange Rose Theodora Morera, Philippe Roger Meyer, Alain Jean Cozzone, Raphael Terreux
-
Publication number: 20140114052Abstract: Methods to synthesize self-assembling peptides embedded with complex organic electronic subunits are provided.Type: ApplicationFiled: October 22, 2012Publication date: April 24, 2014Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: John D. Tovar, Allix M. Sanders
-
Publication number: 20140113875Abstract: The present invention provides herein the design of monodisperse, amphiphilic anticancer drugs—which are now termed “drug amphiphiles” (DAs)—that can spontaneously associate into discrete, stable supramolecular nanostructures with the potential for self-delivery (no additional carriers are needed). The quantitative drug loading in the resulting nanostructures is ensured by the very nature of the molecular design. The DA is a composition comprising: D-L-PEP; wherein D is 1 to 4 hydrophobic drug molecules which can be the same or different; L is 1 to 4 biodegradable linkers which can be the same or different; and PEP is a peptide that can spontaneously associate into discrete, stable supramolecular nanostructures. In an alternate embodiment, the DA composition also comprises a targeting ligand (T). Methods of making DA molecules, as well as their use in treatment of disease are also provided.Type: ApplicationFiled: October 2, 2013Publication date: April 24, 2014Applicant: The Johns Hopkins UniversityInventors: Honggang Cui, Andrew G. Cheetham, Pengcheng Zhang
-
Publication number: 20140113858Abstract: There are provided an angiopoietin-2 (Ang2) derived peptides, polypeptides, and peptide complexes, and a method for inhibition of binding between Ang2 and integrin and prevention and/or treatment of a disease caused by the activation of Ang2 or the binding between Ang2 and integrin using the peptide, polypeptides, and peptide complexes.Type: ApplicationFiled: October 18, 2013Publication date: April 24, 2014Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: SANG YEUL HAN, CHUNG HO KIM, KYUNG EUN KIM, HYUNG-CHAN KIM, KWANG-HOON LEE, HYO SEON LEE
-
Patent number: 8703911Abstract: The invention provides a pharmaceutical composition including a peptide comprising at least a portion of a chemokine receptor or a G-protein coupled receptor and optionally a cytokine. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis and asthma. The invention also provides peptides that may be used in the pharmaceutical composition and a method for preparing the pharmaceutical composition of the invention. The invention further provides a method for to treating an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, and psoriasis asthma.Type: GrantFiled: March 18, 2007Date of Patent: April 22, 2014Assignee: SymThera Canada Ltd.Inventors: Chai Ezerzer, Nicholas Harris
-
Publication number: 20140107041Abstract: The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 ?M), and dimer and multimeric constructs comprising these polypeptides.Type: ApplicationFiled: September 5, 2013Publication date: April 17, 2014Applicant: DYAX CORP.Inventors: AARON K. SATO, DANIEL J. SEXTON, DANIEL T. DRANSFIELD, ROBERT CHARLES LADNER, CHRISTOPHE ARBOGAST, PHILIPPE BUSSAT, HONG FAN, SUDHA KHURANA, KAREN E. LINDER, EDMUND R. MARINELLI, PALANIAPPA NANJAPPAN, ADRIAN NUNN, RADHAKRISHNA PILLAI, SYBILLE POCHON, KONDAREDDIAR RAMALINGAM, AJAY SHRIVASTAVA, BO SONG, ROLF E. SWENSON, MATTHEW A. VON WRONSKI
-
Patent number: 8697836Abstract: Telomerase peptides that bind MHC are disclosed. The instant application also discloses vaccines containing said peptides and methods of using said peptides to enhance a CTL response against mammalian cancer cells.Type: GrantFiled: April 25, 2008Date of Patent: April 15, 2014Assignee: The Regents of the University of CaliforniaInventor: Maurizio Zanetti
-
Patent number: 8697629Abstract: A method of treating a disease characterized by aberrant cell migration and/or invasion includes administering to a subject an effective amount of the peptide of SEQ ID NO:3, an ?6 polypeptide, or an isolated polypeptide consisting essentially of the Link region of human CD44 as indicated in FIG. 17 to modulate a FAK signal transduction pathway for a sufficient period of time to treat the disease. A method of diagnosing a condition characterized by aberrant cell migration and/or invasion includes measuring the effect of these polypeptides on FAK signal transduction activity; wherein a change in FAK signal transduction activity is indicative of said aberrant cell migration or invasion. A method of diagnosing a condition characterized by aberrant cell migration and/or invasion includes imaging FAK signal transduction activity in the presence of these polypeptides.Type: GrantFiled: March 4, 2011Date of Patent: April 15, 2014Assignee: Angstrom Pharmaceuticals, Inc.Inventors: Malcolm Finlayson, Bassam B. Damaj
-
Patent number: 8697840Abstract: During lung injury, p53 expression increases, inducing plasminogen activator inhibitor-1 (PAI-1) while inhibiting expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR), resulting in apoptosis of lung epithelial cells (LECs). In the bleomycin lung injury model, p53 and PAI-1 are induced while uPA and uPAR are inhibited. A 20 residue peptide DGIWKASFTTFTVTKYWFYR termed PP-1 (the Cav-1 scaffolding domain) or peptide NYHYLESSMTALYTLGH, termed PP-2, protected LECs from bleomycin-induced apoptosis in vitro and in vivo and prevented subsequent pulmonary fibrosis by attenuating lung epitheilial damage. Pharmaceutical compositions, peptide multimers and deliverable polypeptides comprising the above peptides are dislcosed.Type: GrantFiled: March 5, 2009Date of Patent: April 15, 2014Assignee: Board of Regents, The University of Texas SystemInventors: Sreerama Shetty, Steven Idell
-
Patent number: 8697031Abstract: The invention relates to micelles that are elaborated with functionality useful for imaging and/or selectively targeting tissue, e.g., in the delivery of hydrophobic agents.Type: GrantFiled: June 2, 2005Date of Patent: April 15, 2014Assignee: Case Western Reserve UniversityInventors: Hua Ai, Jeffrey L. Duerk, Chris Flask, Jinming Gao, Jonathan S. Lewin, Xintao Shuai, Brent Weinberg
-
Patent number: 8697631Abstract: Isolated peptides composed of the amino acid sequence of SEQ ID NO: 33 or fragments thereof that bind to HLA antigens and have cytotoxic T lymphocyte (CTL) inducibility and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical agents, substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors.Type: GrantFiled: December 13, 2010Date of Patent: April 15, 2014Assignee: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
-
Publication number: 20140100354Abstract: Novel peptoids are disclosed that have a formula represented by the following formulae Ia and Ib: wherein X, Y, R, and n are as described herein. The peptoids demonstrate catalytic activity and are useful in substrate-selective catalytic transformations, including asymmetric catalytic transformations.Type: ApplicationFiled: October 4, 2012Publication date: April 10, 2014Inventors: Kent KIRSHENBAUM, Galia Maayan, Michael Ward
-
Publication number: 20140099696Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.Type: ApplicationFiled: April 30, 2013Publication date: April 10, 2014Applicant: Ansun Biopharma, Inc.Inventors: Michael P. Malakhov, Fang Fang
-
Publication number: 20140099359Abstract: A synthetic platelet includes a biocompatible flexible nanoparticle that includes an outer surface and a plurality of peptides conjugated to the surface, the peptides including a plurality of von Willebrand factor-binding peptides (VBPs), collagen-binding peptides (CBPs) and an active platelet GPIIb-IIIa-binding peptides (GBPs).Type: ApplicationFiled: April 13, 2012Publication date: April 10, 2014Applicant: Case Western Reserve UniversityInventors: Anirban Sen Gupta, Madhumitha Ravikumar
-
Patent number: 8691195Abstract: The present invention relates to a transforming growth factor-beta (TGF-?)-mimicking peptide containing a particular amino acid sequence and a composition for preventing or treating TGF-?-effective disorders or conditions using the same. The peptide of the present invention may be much higher stability than natural-occurring TGF-? and improve drawbacks caused by high molecular weight of natural-occurring TGF-?. The peptide of this invention can be advantageously applied to treatment or improvement of TGF-?-effective disorders or conditions and have excellent efficacies on skin whitening and wrinkle improvement.Type: GrantFiled: April 14, 2009Date of Patent: April 8, 2014Assignee: Caregen Co., Ltd.Inventors: Young Ji Chung, Young Deug Kim, Eun Mi Kim, Jeong Jin Choi, Jun Young Choi
-
Patent number: 8691189Abstract: The present disclosure describes techniques used for colorectal cancer detection. Position and distribution of colorectal cancer tumor are detected through nuclear imaging. Alternatively, stage of colorectal cancer is identified by shading value in tumor. Thus, the present disclosure provides a safe and noninvasive clinical method for diagnosing and tracing level and distribution of colorectal cancer before and after treatment.Type: GrantFiled: February 14, 2011Date of Patent: April 8, 2014Assignee: Institute of Nuclear Energy Research, Atomic Energy CouncilInventors: Siao-Syun Guan, Chun-Chia Cheng, Shui-Cheng Lee, Hsien-Ming Wu
-
Patent number: 8691945Abstract: There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.Type: GrantFiled: April 27, 2007Date of Patent: April 8, 2014Assignees: Singapore Health Services Pte Ltd., Agency for Science, Technology and ResearchInventors: Roger Beuerman, Lei Zhou, Shouping Liu, Jing Li, Anita Suresh, Chandra Shekhar Verma, Donald Tan
-
Publication number: 20140094586Abstract: An HLA-binding peptide binding to a HLA-A type molecule, the HLA-binding peptide includes at least one type of amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 80, and consists of not less than 8 and not more than 11 amino acid residues. All of these amino acid sequences herein mentioned are the predicted amino acid sequences binding to a human HLA-A type molecule with the prediction program using the certain active learnig method.Type: ApplicationFiled: March 15, 2013Publication date: April 3, 2014Applicants: KOCHI UNIVERSITY, NEC CORPORATIONInventors: NEC Corporation, Kochi University
-
Publication number: 20140094415Abstract: The invention provides novel potent inhibitors of the ternary protein complex of nNOS, PSD-95, and the NMDA receptor and pharmaceutical compositions comprising the inhibitors for prophylaxis and/or treatment of excitotoxic-related disease and chronic pain conditions in a subject. The inhibitors are dimeric PSD-95 inhibitors comprising a first peptide or peptide analogue linked to a second peptide or peptide analogue by a linker, wherein the first and the second peptide or peptide analogue comprise at least four amide-bonded residues having a sequence YTXV or YSXV, wherein a. Y is selected from among E, Q, and A, or an analogue thereof, and b. X is selected from among A, Q, D, N,N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof, and wherein a Cell Penetrating Peptide (CPP) is linked to the linker or to an amino acid side chain of the first and second peptide or peptide analogue. The linker can be a PEG or NPEG linker.Type: ApplicationFiled: May 11, 2012Publication date: April 3, 2014Inventors: Anders Bach, Kristian Stromgaard
-
Publication number: 20140093521Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.Type: ApplicationFiled: November 26, 2013Publication date: April 3, 2014Applicant: ABBVIE INC.Inventors: Lorenzo Benatuil, Erwin R. Boghaert, Jijie Gu, Maria Harris, Jonathan A. Hickson, Chung-Ming Hsieh, Yuliya Kutskova, Yingchun Li, Zhihong Liu, Susan Morgan-Lappe
-
Patent number: 8685933Abstract: The invention relates to peptides and, in particular, heptapeptides derived from milk casein ?s1 and having anxiolytic activity. The invention also relates to pharmaceutical and food compositions containing said peptides and to the preparation methods thereof.Type: GrantFiled: December 13, 2007Date of Patent: April 1, 2014Assignee: Universite de LorraineInventors: Frederique Balandras, Laurent Miclo, Jean-Luc Gaillard, Yves Le Roux, Francois Laurent
-
Patent number: 8685399Abstract: The present invention relates to anti-human PAX 5 antibodies capable of binding to one or more epitopes located within the C-terminal regulatory domain of PAX 5. In particular the invention relates to an antibody, antigen binding fragment or recombinant protein thereof, which is capable of specific binding to an epitope located within the C-terminal fragment of human PAX 5 protein, wherein said epitope comprises from 3 to 17 amino acid residues of amino acid sequence GSPYYYSAAARGAAPPA (SEQ ID NO:2). The invention also relates to immunogenic peptide sequences for the production of the antibodies, diagnostic and therapeutic applications comprising using the antibodies and formulations comprising thereof.Type: GrantFiled: June 25, 2009Date of Patent: April 1, 2014Assignee: Dako Denmark A/SInventors: Kirsten Damgaard Hoff, Jakob O. Gjørret, Kurt Pii, Sussie Steen Jensen, Henrik Winther
-
Patent number: 8685921Abstract: Provided herein are compounds that inhibit a binding interaction between a ? integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.Type: GrantFiled: September 15, 2012Date of Patent: April 1, 2014Assignee: The Board of Trustees of the University of IllinoisInventor: Xiaoping Du
-
Patent number: 8685955Abstract: Novel iron chelators exhibiting neuroprotective and good transport properties are useful in iron chelation therapy for treatment of a disease, disorder or condition associated with iron overload and oxidative stress, e.g., a neurodegenerative or cerebrovascular disease or disorder, a neoplastic disease, hemochromatosis, thalassemia, a cardiovascular disease, diabetes, an inflammatory disorder, anthracycline cardiotoxicity, a viral infection, a protozoal infection, a yeast infection, retarding aging, and prevention and/or treatment of skin aging and skin protection against sunlight and/or UV light. The iron chelator function is provided by a 8-hydroxyquinoline, a hydroxypyridinone or a hydroxamate moiety. The neuroprotective function is imparted to the compound, e.g., by a neuroprotective peptide. A combined antiapoptotic and neuroprotective function is provided by a propargyl group.Type: GrantFiled: November 14, 2011Date of Patent: April 1, 2014Assignees: Technion Research and Development Foundation Ltd., Yeda Research and Development Co. Ltd.Inventors: Moussa B. H. Youdim, Matitiyahu Fridkin, Hailin Zheng, Rivka Warshawsky
-
Publication number: 20140086924Abstract: Disclosed herein are compounds that inhibit Hsp90 interactions with IAP proteins, such as Survivin, XIAP, cIAP1, or cIAP2, and methods for identifying and using such compounds.Type: ApplicationFiled: April 12, 2013Publication date: March 27, 2014Inventor: University of Massachusetts
-
Publication number: 20140088290Abstract: The present invention relates to novel melanoma antigen peptides and specific T lymphocytes directed to said peptides and the use thereof for treating melanoma.Type: ApplicationFiled: November 21, 2013Publication date: March 27, 2014Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), Chu Nantes, Universite de NantesInventors: Nathalie Labarriere, Agnes Moreau-Aubry, Yann Godet
-
Publication number: 20140086981Abstract: Peptides of general formula (I): R1—Wn—Xm-AA1-AA2-AA3-AA4-AA5-AA6-Yp—Zq—R2 their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, a preparation process, cosmetic or pharmaceutical compositions which contain them and their use in the treatment and/or care of conditions, disorders and/or diseases which improve or are prevented by PGC-1? modulation.Type: ApplicationFiled: March 23, 2012Publication date: March 27, 2014Inventors: José María García Antón, Nuria Almiñana Domenech, Antonio Vicente Ferrer Montiel
-
Patent number: 8680056Abstract: A novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed.Type: GrantFiled: May 3, 2007Date of Patent: March 25, 2014Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Maryland, Baltimore, The United States of America as Represented by the Department of Veterans AffairsInventors: Susan K. Keay, Zoltan Szekely, Thomas Conrads, Timothy Veenstra, Maria Michejda
-
Patent number: 8680058Abstract: The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.Type: GrantFiled: November 2, 2010Date of Patent: March 25, 2014Assignees: The Regents of the University of California, C3 Jian, Inc.Inventors: Randal H. Eckert, Daniel K. Yarbrough, Wenyuan Shi, Maxwell H. Anderson, Fengxia Qi, Jian He, Ian H. McHardy
-
Publication number: 20140080997Abstract: A safe and efficient recombinant mite allergen is provided as a therapeutic agent or a diagnostic agent for mite allergic diseases, which contains no anaphylaxis-inducing impurities. The following recombinant protein (a) or (b) is provided: (a) a protein comprising the amino acid sequence represented by SEQ ID NO: 2 or 35; or (b) a protein comprising an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 or 35 by deletion, substitution, or addition of one or several amino acids and having mite allergen activity.Type: ApplicationFiled: October 14, 2013Publication date: March 20, 2014Applicant: NIPPON ZENYAKU KOGYO CO., LTD.Inventors: Toshihiro TSUKUI, Hajime TSUJIMOTO, Shigehiro IWABUCHI
-
Publication number: 20140080998Abstract: An acid-cleavable peptide linker comprising aspartic acid and proline residues is disclosed. The acid-cleavable peptide linker provides an altered sensitivity to acid-hydrolytic release of peptides of interest from fusion peptides of the formula PEP1-L-PEP2. The inventive linker, L, is described in various embodiments, each of which provides substantially more rapid acid-release of peptides of interest than does a single aspartic acid-proline pair. In an additional aspect, a method of increasing the stability of an acid cleavable linkage to acid hydrolysis is also provided.Type: ApplicationFiled: November 12, 2013Publication date: March 20, 2014Applicant: E I DU PONT DE NEMOURS AND COMPANYInventors: LAURA A BEDZYK, Stephen R. Fahnestock, Tanja Maria Gruber, Daniel P. O'Keefe, Pierre E Rouviere
-
Publication number: 20140082769Abstract: The present application belongs to the field of functional peptides and more particularly to the field of controlled protein aggregation. The invention discloses molecules of a peptide structure as defined in the claims and methods of using such molecules for therapeutic applications and for diagnostic uses, as well as in other applications such as in the agbio field and in industrial biotechnology. The molecules can be used for curing and/or stabilizing infections such as bacterial, fungal and viral diseases, but are also useful in non-infectious human and veterinary diseases. The molecules can also be used for the detection of protein biomarkers and for the prognosis and diagnosis of a variety of diseases.Type: ApplicationFiled: March 12, 2012Publication date: March 20, 2014Inventors: Joost Schymkowitz, Frederic Rousseau
-
Publication number: 20140080147Abstract: The present invention relates to novel CD3 epsilon peptides, antibodies against the novel CD3 epsilon peptides. The invention also relates to methods of identifying an immunodeficiency (such as severe combined immunodeficiency (SCID) or a T cell immunodeficiency) in a patient, which may involve antibodies against CD3 epsilon peptides.Type: ApplicationFiled: August 16, 2013Publication date: March 20, 2014Applicant: Health Research, Inc.Inventors: Kenneth A. Pass, Barbara Lindau-Shepard, David K. Janik
-
Publication number: 20140079701Abstract: The invention is based, at least in part, on the finding that linker peptides which lack the amino acid sequence GSG reduce or eliminate the addition of posttranslational modifications to the polypeptides which comprise them. More specifically, the novel linker peptides disclosed herein reduce the ability of enzymes to link carbohydrate adducts to polypeptides comprising these linker peptides, e.g., reduce the ability of xylosyltransferase to link xylose to polypeptides. These novel linker peptides, molecules comprising same, and methods of their use are described.Type: ApplicationFiled: December 22, 2011Publication date: March 20, 2014Applicant: BIOGEN IDEC MA INC.Inventors: Brian Robert Miller, Scott Glaser, Justin Caravella, Susan Foley, Xiaoping Hronoeski, Tigran Dikran Alvazian
-
Publication number: 20140080156Abstract: This invention relates to a peptide comprising or consisting of at least 8 consecutive amino acid residues of the sequence set forth in SEQ ID NO: 3, provided that said peptide does not consist of the sequence set forth in SEQ ID NO: 3, or a corresponding peptidomimetic, wherein said peptide or peptidomimetic binds to an anti-KIR4.1 antibody comprised in a sample from a patient, said patient having multiple sclerosis or a predisposition therefor, wherein preferably (i) said at least 8 consecutive amino acid residues are a subsequence of an extracellular domain of KIR4.1, said extracellular domain consisting of the sequence set forth in SEQ ID NO: 1 or 2; or (ii) said peptide comprises or consists of the sequence of SEQ ID NO: 1 or 2. The present invention furthermore relates to a method for diagnosing multiple sclerosis or a predisposition for multiple sclerosis in a subject, the method comprising determining the presence of an anti-KIR4.Type: ApplicationFiled: May 23, 2012Publication date: March 20, 2014Applicant: Klinikum rechts der Isar der Technischen Universität MünchenInventors: Bernhard Hemmer, Rajneesh Srivastava
-
Patent number: 8674069Abstract: According to the present invention, peptides having the amino acid sequence of SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62 were demonstrated to have cytotoxic T lymphocyte (CTL) inducibility. Therefore, the present invention provides a peptide having the amino acid sequence selected from among SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62. The peptide can include one, two, or several amino acid substitutions, deletions, insertions, or additions so long as its CTL inducibility is retained. Furthermore, the present invention provides pharmaceutical agents for the treatment and/or prophylaxis of cancers, and/or prevention of postoperative recurrence thereof, which contain any of these peptides. Pharmaceutical agents of this invention include vaccines.Type: GrantFiled: July 30, 2009Date of Patent: March 18, 2014Assignee: OncoTherapy Science, Inc.Inventors: Takuya Tsunoda, Ryuji Ohsawa
-
Patent number: 8673849Abstract: The present invention relates to monomeric and multimeric peptidic compounds which have antiviral activity, particularly against integrin-using viruses, more particularly against rotavirus. Further, the present invention refers to compositions comprising said peptidic compounds for medical use or for use as food additives.Type: GrantFiled: May 31, 2011Date of Patent: March 18, 2014Assignee: ROTALACTIS SrlInventors: Amedeo Conti, David Lembo, Claudio Fabris, Enrico Bertino, Santo Landolfo
-
Patent number: 8674060Abstract: Loss of Wnt-5a protein expression in breast carcinoma patients is associated with a shorter recurrence-free survival as well as increased motility in mammary cell lines. Based on sequence analysis of Wnt-5a, peptide fragments were identified and investigated for their ability to mimic effects of the Wnt-5a protein on mammary cell adhesion and motility. Two of these peptides significantly increased adhesion and impaired the motility of non-tumorigenic breast cancer cell lines, both low in endogenous Wnt-5a protein expression. To identify the shortest possible peptide that still had an anti-motile effect, sequential deletions of two amino acids from the N-terminal side of the shorter of these two peptides were performed. The effect on tumor cell adhesion was gradually lost, and when only 6 amino acids remained the effect was not detectable. However, formulation of the N-terminal methionine of this hexapeptide restored its effect on adhesion and reduced tumor cell motility.Type: GrantFiled: November 28, 2007Date of Patent: March 18, 2014Assignee: Wntresearch ABInventor: Tommy Andersson
-
Patent number: 8673270Abstract: The invention provides RGD-containing cyclic peptidomimetics; conjugates of said peptidomimetics and a moiety of a payload selected from fluorescent probes, photosensitizers, chelating agents, or cytotoxic agents; and pharmaceutical compositions comprising these conjugates. The conjugates of the invention are useful both for diagnostic purposes and treatment of various diseases, disorders and conditions. More specifically, conjugates comprising fluorescent probes can be used for diagnostic purposes, e.g., visualization of organs and tissues, and diagnosis of tumors; conjugates comprising photosensitizers can be used for photodynamic therapy of both tumors and nonneoplastic tissues; conjugates comprising chelating agents can be used in radio imaging or radiotherapy; and conjugates comprising cytotoxic agents can be used for in targeted chemotherapy.Type: GrantFiled: October 22, 2009Date of Patent: March 18, 2014Assignee: Steba Biotech S.A.Inventors: Doron Eren, Tamar Yechezkel, Yoseph Salitra, Natalia Koudinova
-
Publication number: 20140072565Abstract: The present invention relates to a novel epitope to convert T cell to type 17 helper T (TH17) cell. Specifically, the present invention relates to an epitope constituting the 41st to 50th amino acids (SEQ ID No. 2) of extracellular domain (ECD) of activation-inducible tumor necrosis factor receptor (AITR), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting T cell to TH17 cell and a method of conversion for the same, a pharmaceutical composition comprising the antibody for preventing or treating infectious disease, a method for treating infectious disease using the antibody, a composition comprising the antibody for enhancing immunity, and a method, for enhancing immunity using the antibody.Type: ApplicationFiled: April 12, 2013Publication date: March 13, 2014Applicant: National Cancer CenterInventor: National Cancer Center
-
Publication number: 20140073761Abstract: Described herein are compositions and methods for use in targeted drug delivery using cell receptor binding drug delivery conjugates containing hydrophilic spacer linkers for use in imaging, diagnosing, and/or treating diseases and disease states caused by pathogenic cell populations.Type: ApplicationFiled: March 5, 2013Publication date: March 13, 2014Applicant: ENDOCYTE, INC.Inventor: ENDOCYTE, INC.
-
Publication number: 20140073556Abstract: The present invention discloses novel peptides derived from the IL-1 receptor antagonist protein (IL1 RA), capable of binding to the cell surface IL-1 receptor 1 (IL1 R1) and interfere with the binding of IL-1 to IL1 R1. This binding thus effectively antagonises the inflammatory effects of IL-1, such as by reducing TNF-alpha secretion from macrophages. This is of potential use as an anti-inflammatory factor throughout the human body, including the central nervous system. The use of said peptides as anti-inflammatory agents for treatment of pathological conditions wherein IL-1 plays a prominent role, such as inflammatory conditions of the body and the central nervous system, is thus an aspect of the present invention.Type: ApplicationFiled: March 14, 2012Publication date: March 13, 2014Applicant: SERODUS ASAInventors: Vladimir Berezin, Elisabeth Bock
-
Patent number: 8669230Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells which can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: October 29, 2010Date of Patent: March 11, 2014Assignee: Immatics Biotechnologies GmbHInventors: Harpreet Singh, Steffen Walter, Toni Weinschenk, Norbert Hilf, Oliver Schoor, Claudia Lemmel
-
Publication number: 20140065152Abstract: The present invention relates to a novel epitope that converts T cell to type 1 helper T (TH1) cell. Specifically, the present invention relates to an epitope constituting the 56th to 65th amino acids (SEQ ID No. 2) of extracellular domain (ECD) of activation-inducible tumor necrosis factor receptor (AITR), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting T cell to TH1 cell and a method for converting T cell to TH1 cell, a pharmaceutical composition comprising the antibody for preventing or treating cancer, a method for treating cancer using the antibody, a composition comprising the antibody for enhancing immunity, and a method for enhancing immunity using the antibody.Type: ApplicationFiled: April 12, 2013Publication date: March 6, 2014Applicant: National Cancer CenterInventor: Byoung Se KWON